Guest editor: Stephan Beck
Large-scale sequencing and high-throughput studies of a wide variety of cancers are revealing epigenomic variations, including DNA methylation and histone modifications, as well as mutations in genes involved in epigenetic regulation. These findings are providing insights into cancer initiation and progression, are allowing the identification and development of epigenetic biomarkers for diagnosis, prognosis or therapeutic response, and are revealing novel approaches and targets for therapeutic intervention. Genome Medicine presents a series of articles focusing on cancer epigenomics, with commissioned comment and review articles, and original research, featuring the latest advances and translational findings with the potential to inform new approaches for screening, diagnosis, prevention and treatment of cancer.
This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process. The Guest Editor declares no competing interests.